2023
Appendiceal adenocarcinoma is associated with better prognosis than cecal adenocarcinoma: a population-based comparative survival study
Chen G, Chen K, Sahyoun L, Zaman S, Protiva P. Appendiceal adenocarcinoma is associated with better prognosis than cecal adenocarcinoma: a population-based comparative survival study. BMJ Open Gastroenterology 2023, 10: e001045. PMID: 36822658, PMCID: PMC9950880, DOI: 10.1136/bmjgast-2022-001045.Peer-Reviewed Original ResearchConceptsCecal adenocarcinomaAppendiceal adenocarcinomaCox regression analysisAppendiceal cancerMantel-Haenszel log-rank testColorectal cancer screening ratesMultivariable Cox regression analysisCounty-level socioeconomic factorsCancer screening ratesEnd Results (SEER) databaseKaplan-Meier methodRare gastrointestinal malignancyLog-rank testNon-mucinous histologySingle marital statusNon-Hispanic ethnicityYears of ageComparative survival analysisComparative survival studyRegression analysisSAS V.9.4Gastrointestinal malignanciesOverall survivalBetter prognosisChemotherapy protocols
2021
Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response
Hajiran A, Chakiryan N, Aydin A, Zemp L, Nguyen J, Laborde J, Chahoud J, Spiess P, Zaman S, Falasiri S, Fournier M, Teer J, Dhillon J, McCarthy S, Moran-Segura C, Katende E, Sexton W, Koomen J, Mulé J, Kim Y, Manley B. Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response. Clinical & Experimental Immunology 2021, 204: 96-106. PMID: 33346915, PMCID: PMC7944355, DOI: 10.1111/cei.13567.Peer-Reviewed Original ResearchConceptsMetastatic clear cell renal cell carcinomaClear cell renal cell carcinomaTumor immune microenvironmentRenal cell carcinomaT-betOverall survivalCell carcinomaMetastatic renal cell carcinomaForkhead box protein 3Improved overall survivalCell renal cell carcinomaCox regression analysisImmune cell distributionT-cell markersPoor overall survivalBox protein 3Tumor-stromal interfaceMetastatic tumor samplesPrecision treatment strategiesTumor-stroma interfaceTumor coreImproved survivalImmune markersImmunotherapy responsePoor outcome